Achillion Pharmaceuticals, Inc. (ACHN) Raised at Piper Jaffray, Wells Fargo

Shares of Achillion Pharmaceuticals, Inc. (ACHN) are up almost 8% to $7.93 in pre-market trading Monday. The spike may be attributed to an upgrade to ‘Overweight’ from ‘Neutral’ and a $10.00 from $5.00 price target at Piper Jaffray, which represents expected upside of 35.86% to the stock’s previous closing price of $7.36.

From a sentiment standpoint, ACHN, which was also upgraded to ‘Outperform’ from ‘Market Perform’ at Wells Fargo (WFC) this morning, has a number of analysts already in the bullish camp, as the biotech company boasts 2 “Strong Buys”, 4 ‘Buys’, 5 ‘Holds’ and not a single “Sell.”

On valuation-measures, shares of Achillion Pharmaceuticals have a P/E to growth ratio of -1.91 and a t-12 negative return on equity of -37.97%. EPS is at -$0.65. The company has a market cap of $712 million and a median Wall Street price target of $11.00 with a high target of $22.00. Achillion last announced its earnings results on August 7th, reporting a Q2’14 net loss of $15.7 million compared with a net loss of $19.9 million during the same period of FY2013.

ACHN has a beta of 1.80 and a short float of 35.20%. In the past 52 weeks, shares of Achillion Pharmaceuticals have traded between a low of $2.26 and a high of $8.61. The pharma company reported $140 million in cash vs. $256.000 in debt in its most recent quarter. ACHN is currently printing a one year return of about 15% and a year-to-date return of around 121.75%.

The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.

Achillion Pharmaceuticals, Inc., develops and commercializes anti-infective drug therapies in the U. S. and internationally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Create Content With AI

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.